SHEL.UK

2,805.5

+0.2%↑

BP

462.1

+0.47%↑

SHEL.UK

2,805.5

+0.2%↑

BP

462.1

+0.47%↑

SHEL.UK

2,805.5

+0.2%↑

BP

462.1

+0.47%↑

SHEL.UK

2,805.5

+0.2%↑

BP

462.1

+0.47%↑

SHEL.UK

2,805.5

+0.2%↑

BP

462.1

+0.47%↑

Search

Smith & Nephew PLC

Atvērts

1,238 0.24

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

1220

Max

1241.5

Galvenie mērījumi

By Trading Economics

Ienākumi

296M

Pārdošana

3B

P/E

Sektora vidējais

29.619

22.253

EPS

0.429

Dividenžu ienesīgums

3.04

Peļņas marža

9.895

Darbinieki

17,000

EBITDA

723M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+18.75% upside

Dividendes

By Dow Jones

Dividenžu ienesīgums

Sektora vidējais

3.04%

4.31%

Nākamie ieņēmumi

2026. g. 2. marts

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

1.6B

11B

Iepriekšējā atvēršanas cena

1237.76

Iepriekšējā slēgšanas cena

1238

Smith & Nephew PLC Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 3. dec. 23:21 UTC

Peļņas
Iegādes, apvienošanās, pārņemšana

EQB to Buy Loblaw Unit PC Financial for About $573.5 Million -- Update

2025. g. 3. dec. 23:14 UTC

Iegādes, apvienošanās, pārņemšana

EQB to Buy PC Financial From Loblaw for About $573.5 Million

2025. g. 3. dec. 22:01 UTC

Galvenie tirgus virzītāji

Costco Wholesale Reports Higher Monthly Sales

2025. g. 3. dec. 21:38 UTC

Peļņas

Salesforce Raises Revenue Forecast as Agentforce Sales Top $500 Million

2025. g. 3. dec. 23:59 UTC

Tirgus saruna

Australian Coal Prices Seen Having Recovered Well -- Market Talk

2025. g. 3. dec. 23:49 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 3. dec. 23:49 UTC

Tirgus saruna

HSBC Chair Appointment Unlikely to Have Material Operational Impact -- Market Talk

2025. g. 3. dec. 23:49 UTC

Tirgus saruna

Nikkei May Decline Amid Caution Over U.S. Labor Market -- Market Talk

2025. g. 3. dec. 23:13 UTC

Tirgus saruna

Australian Treasurer Says Economy Not On Drip of Govt Spending -- Market Talk

2025. g. 3. dec. 23:10 UTC

Peļņas

Salesforce Raises Forecast as Agentforce Sales Top $500M -- Update

2025. g. 3. dec. 23:08 UTC

Tirgus saruna

Goodman's New Bull Sees Profit Upgrade on Cards -- Market Talk

2025. g. 3. dec. 23:06 UTC

Iegādes, apvienošanās, pārņemšana

EQB to Buy Loblaw Unit PC Financial for About $573.5M -- Update

2025. g. 3. dec. 22:59 UTC

Iegādes, apvienošanās, pārņemšana

EQB to Buy PC Financial From Loblaw for About $573.5M

2025. g. 3. dec. 22:45 UTC

Tirgus saruna

WiseTech Investor Day Increases Bull's Confidence -- Market Talk

2025. g. 3. dec. 22:20 UTC

Peļņas

Salesforce CEO: 9,500 of 18,500 Total Closed Agentforce Deals Are Paid

2025. g. 3. dec. 22:19 UTC

Peļņas

Salesforce CEO: Six Out of 10 Biggest Deals in 3Q Came from Agentforce

2025. g. 3. dec. 22:17 UTC

Peļņas

Salesforce Working to Add Voice to Agentforce, CEO Says

2025. g. 3. dec. 22:16 UTC

Peļņas

Salesforce CEO: Williams-Sonoma's Agentforce Makes Up 60% of Customer Chats

2025. g. 3. dec. 22:15 UTC

Peļņas

Salesforce CEO: Agentforce ARR Was $540M in 3Q

2025. g. 3. dec. 22:10 UTC

Iegādes, apvienošanās, pārņemšana

EQB: Will Enter Into a Long-Term Strategic Relationship With Loblaw >EQB.T

2025. g. 3. dec. 22:09 UTC

Iegādes, apvienošanās, pārņemšana

EQB: Agreed to Acquire PC Fincl From Loblaw >EQB.T

2025. g. 3. dec. 21:50 UTC

Tirgus saruna

Auto & Transport Roundup: Market Talk

2025. g. 3. dec. 21:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 3. dec. 21:49 UTC

Peļņas

Salesforce Reports Mounting Profits. The Stock Is Rising. -- Barrons.com

2025. g. 3. dec. 21:23 UTC

Peļņas

Salesforce Raises Revenue Forecast as Agentforce Sales Top $500M

2025. g. 3. dec. 21:19 UTC

Peļņas

Salesforce Reports Mounting Profits. The Stock Is Rising. -- Barrons.com

2025. g. 3. dec. 21:06 UTC

Peļņas

Salesforce Reports Mixed Earnings. The Stock Is Rising. -- Barrons.com

2025. g. 3. dec. 21:04 UTC

Peļņas

Salesforce Sees Profitable Growth Framework Target of 50 by FY30 >CRM

2025. g. 3. dec. 21:04 UTC

Peļņas

Salesforce Targets $60 B Plus Organic Rev by FY30 >CRM

2025. g. 3. dec. 21:03 UTC

Peļņas

Salesforce Raises FY26 Oper Cash Flow Growth Guidance to 13% to 14% Y/Y >CRM

Salīdzinājums

Cenas izmaiņa

Smith & Nephew PLC Prognoze

Cenas mērķis

By TipRanks

18.75% augšup

Prognoze 12 mēnešiem

Vidējais 1,464.78 GBX  18.75%

Augstākais 1,700 GBX

Zemākais 1,018.01 GBX

Pamatojoties uz 9 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Smith & Nephew PLC — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

9 ratings

6

Pirkt

3

Turēt

0

Pārdot

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Smith & Nephew PLC

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. It also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg wounds, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. The company serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
help-icon Live chat